AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company that develops disease-modifying therapies for immunology and inflammatory diseases in the United States. Its pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 in Phase 2a trials for fibrostenosing Crohn's disease, and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 in Phase 1 trials for idiopathic pulmonary fibrosis. It also develops AGMB-101, an HGF-mimetic monoclonal antibody that acts through agonism of the MET receptor and has shown antifibrotic and regenerative activity in preclinical models. Incorporated in 2017, the company is headquartered in Antwerp, Belgium.